Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Active, not recruiting · NCT05407636 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-08-03 | NCT05407636 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| REGENXBIO Inc. | 14 |
181 results · Page 1 of 8
Research sites
Swipe the table sideways for more columns.